siRNA and targeted delivery systems in breast cancer therapy

• Sepideh Mirzaei ^[1] ; Mahshid Deldar Abad Paskeh ^[1] ; Maliheh Entezari ^[1] ; Seyed Hesamoddin Bidooki ^[3] ; Vahideh Javadian Ghaleh ^[1] ; Shamin Rezaei ^[1] ; Elahe Sadat Hejazi ^[1] ; Amirabbas Kakavand ^[1] ; Mitra Behroozaghdam ^[1] ; Abolfazl Movafagh ^[2] ; Afshin Taheriazam ^[1] ; Mehrdad Hashemi ^[1] ; Saeed Samarghandian ^[4]
  1. [1] Islamic Azad University

     Islamic Azad University

     Irán

     
  2. [2] Shahid Beheshti University of Medical Sciences

     Shahid Beheshti University of Medical Sciences

     Irán

     
  3. [3] Departamento de Bioquímica y Biología Molecular y Celular, Facultad de Veterinaria, Instituto de Investigación Sanitaria Aragón-Universidad de Zaragoza, 50013, Zaragoza, España
  4. [4] Healthy Ageing Research Centre, Neyshabur University of Medical Sciences, Neyshabur, Iran

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 25, Nº. 5 (May), 2023, págs. 1167-1188
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Recently, nucleic acid drugs have been considered as promising candidates in treatment of various diseases, especially cancer. Because of developing resistance to conventional chemotherapy, use of genetic tools in cancer therapy appears inevitable. siRNA is a RNAi tool with capacity of suppressing target gene. Owing to overexpression of oncogenic factors in cancer, siRNA can be used for suppressing those pathways. This review emphasizes the function of siRNA in treatment of breast tumor. The anti-apoptotic-related genes including Bcl-2, Bcl-xL and survivin can be down-regulated by siRNA in triggering cell death in breast cancer. STAT3, STAT8, Notch1, E2F3 and NF-κB are among the factors with overexpression in breast cancer that their silencing by siRNA paves the way for impairing tumor proliferation and invasion. The oncogenic mechanisms in drug resistance development in breast tumor such as lncRNAs can be suppressed by siRNA. Furthermore, siRNA reducing P-gp activity can increase drug internalization in tumor cells. Because of siRNA degradation at bloodstream and low accumulation at tumor site, nanoplatforms have been employed for siRNA delivery to suppress breast tumor progression via improving siRNA efficacy in gene silencing. Development of biocompatible and efficient nanostructures for siRNA delivery can make milestone progress in alleviation of breast cancer patients.